- Oragenics (OGEN +3.7%) and Intrexon (XON +0.5%) establish an Exclusive Channel Collaboration for the development and commercialization of "genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus."
- The companies intends to initially focus on a treatment for oral lesions associated with Behcet's. (PR)
- Previous: XON, OGEN announce results from lantibiotics testing
Oragenics, Intrexon in deal to develop genetically modified probiotics
Oct 1 2013, 10:08 ET